glp 1 agonist news Researchers find GLP-1 medications safe to continue before surgery in patients with diabetes and obesity The Power of Discovery: GLP-1

NAION The effect of GLP-1 RAs on NAION is inconsistent across studies

Crucially, they trigger insulin release only when glucose is already present in the bloodstream, minimizing the risk of dangerous hypoglycemia seen with some older diabetes drugs

SGA, small-for-gestational-age, was defined as being in the lowest 10th percentile when compared within groups of the same calendar year, the same sex, and the same gestational age category

Interestingly, administration of liraglutide in mice with selective disruption of the cardiomyocyte GLP-1R ( Glp1r CM/ ) generated from MerCreMer transgenic mice expressing tamoxifen-inducible Cre driven by the -myosin heavy chain promoter, still produced robust cardioprotection and increased survival, suggesting that cardiomyocyte GLP-1R activation is not required for adaptive responses to ischemic and cardiomyopathic injury mediated by liraglutide (Ussher et al